This article is part of a Health Affairs Forefront featured topic, Medicaid Financing. Which includes analysis, proposals, and commentary that will inform policies on the state and federal levels to ...

Analysts expect the market for manufacturing cell and gene therapies, worth less than $20 billion in 2024, to expand rapidly as approvals drive higher volumes of production.

Cell and gene therapies (CGTs) are gaining strategic importance across the healthcare landscape, with oncology being the leading therapeutic area followed by cardiovascular and central nervous system ...

The Centers for Medicare & Medicaid Services (CMS) announced Tuesday that 33 states, as well as the District of Columbia and Puerto Rico, have agreed to participate in the Cell and Gene Therapy (CGT) ...

Cell and gene therapies, or CGT, have come a long way since they were first introduced. In the last few decades, both cell therapy -- the transplantation of living cells -- and gene therapy -- the use ...

UCSF scientists found a precise way to turn on cancer-fighting immune cells inside the body. This more potent form of CAR-T ...

Few companies stand better poised than Beam Therapeutics to reap the first fruits of the FDA’s promised flexibility toward cell and gene therapies. The biotech is pioneering treatments based on base ...

Kyoto, Japan -- Cell and gene therapies, or CGT, have come a long way since they were first introduced. In the last few decades, both cell therapy -- the transplantation of living cells -- and gene ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Researchers in the lab of Hans-Peter Kiem, MD, PhD, at Fred Hutch Cancer Center have devised a method that could one day treat genetic hematologic disorders by correcting how the body makes blood ...

A new research project at the Cyprus Institute of Neurology and Genetics (CING) aims to develop a one-time, curative therapy for beta-thalassemia, the most common inherited blood disorder in Cyprus.

A revolutionary treatment brings new hope to those suffering from a devastating rare skin disorder, while showcasing an innovative funding model that could transform rare disease research In a ...